Bio-Path Holdings Announces Successful Completion of Safety Testing in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia
Bio-Path Holdings, Inc. (BPTH)
Last bio-path holdings, inc. earnings: 11/14 04:20 pm
Check Earnings Report
US:NASDAQ Investor Relations:
biopathholdings.com
Company Research
Source: GlobeNewswire
HOUSTON, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announces the successful completion of the safety testing of prexigebersen in combination with decitabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients in Stage 2 of the Phase 2 clinical study. The safety segment of Stage 2 of the Phase 2 clinical trial comprised six evaluable patients who were treated with the combination of prexigebersen and decitabine. “We are especially pleased to have successfully completed this key safety segment of our Phase 2 study as it allows us to move forward to the next segment of this important clinical study, which is the final, efficacy portion of Stage 2 of the Phase 2 study,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings. “We are in t
Show less
Read more
Impact Snapshot
Event Time:
BPTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BPTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BPTH alerts
High impacting Bio-Path Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
BPTH
News
- Bio-Path (BPTH) Could Find a Support Soon, Here's Why You Should Buy the Stock Now [Yahoo! Finance]Yahoo! Finance
- Bio-Path Holdings, Inc. (NASDAQ: BPTH) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Bio-Path Holdings Reports Third Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Bio-Path Holdings Reports Third Quarter 2024 Financial ResultsGlobeNewswire
- Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024GlobeNewswire
BPTH
Earnings
- 11/14/24 - Beat
BPTH
Sec Filings
- 11/15/24 - Form 8-K
- 11/14/24 - Form 10-Q
- 11/13/24 - Form SC
- BPTH's page on the SEC website